Compass Biotechnologies Stock Performance
| BNGI Stock | USD 0.00001 0.00 0.00% |
The firm shows a Beta (market volatility) of 0.0, which signifies not very significant fluctuations relative to the market. the returns on MARKET and Compass Biotechnologies are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Compared to the overall equity markets, risk-adjusted returns on investments in Compass Biotechnologies are ranked lower than 10 (%) of all global equities and portfolios over the last 90 days. Despite fairly weak technical and fundamental indicators, Compass Biotechnologies demonstrated solid returns over the last few months and may actually be approaching a breakup point. ...more
Last Split Factor 1:40 | Last Split Date 2009-02-02 |
Compass Biotechnologies Relative Risk vs. Return Landscape
If you would invest 0.00 in Compass Biotechnologies on September 30, 2025 and sell it today you would earn a total of 0.00 from holding Compass Biotechnologies or generate 9.223372036854776E16% return on investment over 90 days. Compass Biotechnologies is currently generating 15.873% in daily expected returns and assumes 125.9882% risk (volatility on return distribution) over the 90 days horizon. In different words, most equities are less risky than Compass, and most traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Compass Biotechnologies Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Compass Biotechnologies' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Compass Biotechnologies, and traders can use it to determine the average amount a Compass Biotechnologies' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.126
| Best Portfolio | Best Equity | BNGI | ||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Based on monthly moving average Compass Biotechnologies is performing at about 10% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Compass Biotechnologies by adding it to a well-diversified portfolio.
Compass Biotechnologies Fundamentals Growth
Compass Stock prices reflect investors' perceptions of the future prospects and financial health of Compass Biotechnologies, and Compass Biotechnologies fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Compass Stock performance.
| Return On Asset | -0.0336 | ||||
| Current Valuation | 288.1 K | ||||
| Shares Outstanding | 1.43 B | ||||
| Price To Book | 6.47 X | ||||
| EBITDA | (708.94 K) | ||||
| Net Income | (323.81 K) | ||||
| Cash And Equivalents | 31.21 K | ||||
| Total Debt | 78.19 K | ||||
| Current Ratio | 0.08 X | ||||
| Cash Flow From Operations | (6.45 K) | ||||
| Earnings Per Share | (0.01) X | ||||
| Market Capitalization | 14.28 K | ||||
| Total Asset | 111.67 K | ||||
| Retained Earnings | (7.1 M) | ||||
About Compass Biotechnologies Performance
By evaluating Compass Biotechnologies' fundamental ratios, stakeholders can gain valuable insights into Compass Biotechnologies' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Compass Biotechnologies has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Compass Biotechnologies has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 132.05 | 123.65 | |
| Return On Tangible Assets | (6.03) | (6.33) | |
| Return On Capital Employed | (5.32) | (5.05) | |
| Return On Assets | (1.86) | (1.96) | |
| Return On Equity | (6.11) | (5.81) |
Things to note about Compass Biotechnologies performance evaluation
Checking the ongoing alerts about Compass Biotechnologies for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Compass Biotechnologies help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Compass Biotechnologies is way too risky over 90 days horizon | |
| Compass Biotechnologies has some characteristics of a very speculative penny stock | |
| Compass Biotechnologies appears to be risky and price may revert if volatility continues | |
| Compass Biotechnologies currently holds 78.19 K in liabilities. Compass Biotechnologies has a current ratio of 0.08, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Compass Biotechnologies' use of debt, we should always consider it together with its cash and equity. | |
| Net Loss for the year was (323.81 K) with profit before overhead, payroll, taxes, and interest of 0. | |
| Compass Biotechnologies currently holds about 31.21 K in cash with (6.45 K) of positive cash flow from operations. | |
| Compass Biotechnologies has a frail financial position based on the latest SEC disclosures | |
| Latest headline from news.google.com: After-Hours Rally Stoke Therapeutics, Alpha Tau Medical, Compass Pathways Lead Biotech Movers - Nasdaq |
- Analyzing Compass Biotechnologies' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Compass Biotechnologies' stock is overvalued or undervalued compared to its peers.
- Examining Compass Biotechnologies' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Compass Biotechnologies' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Compass Biotechnologies' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Compass Biotechnologies' stock. These opinions can provide insight into Compass Biotechnologies' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Compass Stock analysis
When running Compass Biotechnologies' price analysis, check to measure Compass Biotechnologies' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Compass Biotechnologies is operating at the current time. Most of Compass Biotechnologies' value examination focuses on studying past and present price action to predict the probability of Compass Biotechnologies' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Compass Biotechnologies' price. Additionally, you may evaluate how the addition of Compass Biotechnologies to your portfolios can decrease your overall portfolio volatility.
| Share Portfolio Track or share privately all of your investments from the convenience of any device | |
| Commodity Channel Use Commodity Channel Index to analyze current equity momentum | |
| Bonds Directory Find actively traded corporate debentures issued by US companies |